XDEMVY (TP-03)
Demodex Blepharitis
Key Facts
About Tarsus Pharmaceuticals
Tarsus Pharmaceuticals is a mission-driven biotech focused on revolutionizing treatment for patients by developing novel, mechanism-driven therapeutics. Its landmark achievement is the 2023 FDA approval of XDEMVY® (lotilaner ophthalmic solution) 0.25%, the first and only therapy for Demodex blepharitis, transitioning the company to commercial stage. Tarsus's strategy centers on identifying validated biological targets and repurposing or developing precise small-molecule drugs to address root causes in large markets with limited options. The company is now executing on the commercialization of XDEMVY while advancing a pipeline of 11 candidates, including late-stage programs for Meibomian gland disease and early-stage assets for Lyme disease prevention.
View full company profileTherapeutic Areas
Other Demodex Blepharitis Drugs
| Drug | Company | Phase |
|---|---|---|
| TP-03 (lotilaner) | LianBio | Phase 3 |